Opinions & Features

Valeant Pharmaceuticals is making headlines again as news continues to drip out on its business practices. Recently reports emerged that Valeant, a hedge fund darling, has the option right to acquire a private company called[...]

Insurance companies have a major stake in the national discussion on the cost of drugs. They’re usually pitted against big pharma and biotech, looking for ways to save money on care and drugs. One recent[...]

All day Monday, on TV and Twitter you could hear investors, Big Pharma, biotech executives and politicians all saying the same thing: “What’s next?”

Over 2,500 years ago, Thucydides, known as the father of scientific history because he relied on facts and his observations rather than divine intervention to explain events, once described a plague that struck Athens. As[...]

Just when you think a biotech bear market is about to descend, the bulls come rushing in.

Word of Beau Biden, Jr.’s death stunned the nation. It was a sudden loss, unexpected news that chimed and buzzed over smartphones everywhere and then flashed over television screens across the country.

Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do.

There are very few assurances in life, but in the field of generic pharmaceuticals, there are three certainties we are about to witness

At a little after 12:00 AM Pacific Time consumers will be able to pre-order the Apple Watch online for delivery on April 24th.

Rather than focusing on the noble quest of a few scientists and physicians, we must face the reality that cancer is a business.